BR112019001528A8 - novas formulações de comprimidos de cannabus e composições e métodos de produção do mesmo - Google Patents

novas formulações de comprimidos de cannabus e composições e métodos de produção do mesmo

Info

Publication number
BR112019001528A8
BR112019001528A8 BR112019001528A BR112019001528A BR112019001528A8 BR 112019001528 A8 BR112019001528 A8 BR 112019001528A8 BR 112019001528 A BR112019001528 A BR 112019001528A BR 112019001528 A BR112019001528 A BR 112019001528A BR 112019001528 A8 BR112019001528 A8 BR 112019001528A8
Authority
BR
Brazil
Prior art keywords
compositions
cannabus
new
production methods
tablet formulations
Prior art date
Application number
BR112019001528A
Other languages
English (en)
Other versions
BR112019001528A2 (pt
Inventor
Levy Kurt
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61017335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019001528(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of BR112019001528A2 publication Critical patent/BR112019001528A2/pt
Publication of BR112019001528A8 publication Critical patent/BR112019001528A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

são aqui divulgadas composições compreendendo um óleo tendo pelo menos um canabinóide e pelo menos um pó sólido e métodos para fabricar e usar o mesmo. numa modalidade, as composições aqui divulgadas são adequadas para preparar comprimidos contendo canabinóides pressionando uma composição desta divulgação com um ou mais agentes de formulação, tais como aglutinantes, enchimentos, agentes de volume, excipientes, etc.
BR112019001528A 2016-07-25 2017-07-25 novas formulações de comprimidos de cannabus e composições e métodos de produção do mesmo BR112019001528A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662366517P 2016-07-25 2016-07-25
PCT/US2017/043808 WO2018022669A1 (en) 2016-07-25 2017-07-25 New cannabis tablet formulations and compositions and methods of making the same

Publications (2)

Publication Number Publication Date
BR112019001528A2 BR112019001528A2 (pt) 2019-06-18
BR112019001528A8 true BR112019001528A8 (pt) 2019-07-09

Family

ID=61017335

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001528A BR112019001528A8 (pt) 2016-07-25 2017-07-25 novas formulações de comprimidos de cannabus e composições e métodos de produção do mesmo

Country Status (12)

Country Link
US (3) US20190183850A1 (pt)
EP (1) EP3487482A4 (pt)
CN (1) CN109789095A (pt)
AU (1) AU2017302559A1 (pt)
BR (1) BR112019001528A8 (pt)
CA (1) CA3031533A1 (pt)
CL (1) CL2019000198A1 (pt)
CO (1) CO2019000787A2 (pt)
IL (1) IL264386B2 (pt)
MX (1) MX2019001121A (pt)
PE (1) PE20200478A1 (pt)
WO (1) WO2018022669A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092060A1 (en) * 2018-02-23 2019-08-29 Columbia Care Llc Hard-pressed scored splittable marijuana tablets
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
WO2020092352A1 (en) * 2018-10-30 2020-05-07 Kelsie Biotech, Llc Tablets, formulations and methods for low melting point active ingredients
US20220023220A1 (en) * 2019-01-10 2022-01-27 Columbia Care Llc Rapidly disintegrating oral tablet
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
CA3040547C (en) 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
AU2021206021A1 (en) * 2020-01-08 2022-06-02 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating gastrointestinal disorders
CA3219553A1 (en) * 2021-05-21 2022-11-24 Rama JUDE Process for incorporating additives into aerosol-producing substrates and products made therefrom

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2081474A1 (en) * 1990-05-08 1991-11-09 Manzer Durrani Direct spray-dried drug/lipid powder composition
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
AU2002231970B2 (en) * 2001-02-14 2007-08-16 GW Research Limited Mucoadhesive pharmaceutical formulations
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
CA2664311C (en) * 2006-09-15 2015-08-18 Echo Pharmaceuticals B.V. Granulate containing a pharmaceutically active substance and method for its manufacture
CN101810593B (zh) * 2010-05-10 2012-07-18 谢恬 一种榄香烯缓释片
WO2016014454A1 (en) * 2014-07-21 2016-01-28 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
WO2016084075A1 (en) 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US10172786B2 (en) 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids

Also Published As

Publication number Publication date
US20190183850A1 (en) 2019-06-20
BR112019001528A2 (pt) 2019-06-18
CL2019000198A1 (es) 2019-05-31
AU2017302559A1 (en) 2019-02-07
IL264386B1 (en) 2023-04-01
US20220323403A1 (en) 2022-10-13
US20210100771A1 (en) 2021-04-08
IL264386A (en) 2019-02-28
EP3487482A1 (en) 2019-05-29
EP3487482A4 (en) 2020-03-04
CO2019000787A2 (es) 2019-04-30
MX2019001121A (es) 2019-10-21
CA3031533A1 (en) 2018-02-01
PE20200478A1 (es) 2020-03-03
CN109789095A (zh) 2019-05-21
WO2018022669A1 (en) 2018-02-01
IL264386B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
BR112019001528A2 (pt) novas formulações de comprimidos de cannabus e composições e métodos de produção do mesmo
MX2023010042A (es) Polinucleotidos moduladores.
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
BR112018008877A8 (pt) inibidores de ret
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
BR112019002371A2 (pt) composições farmacêuticas
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
BR112017021126A2 (pt) composição de lignina ativada, método para a sua produção e utilização
EA201900562A1 (ru) Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты
NZ763528A (en) Heterocyclic gpr119 agonist compounds
MX2020011478A (es) Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos.
BR112018013985A2 (pt) glicosídeos de esteviol altamente solúveis
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
WO2020131586A3 (en) Methods for identifying neoantigens
BR112018006730A2 (pt) método para preparar um composto, substância ou mistura de substância, uso de pelo menos uma substância ou mistura de substância, composição de fragrância, e, agente.
BR112016029765A2 (pt) polímeros à base de etileno compreendendo unidades derivadas de monóxido de carbono e um agente de modificação de reologia
MX367669B (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos.
MX2019005855A (es) Formulaciones que se pueden pulverizar.
MX2020008125A (es) Composiciones que comprenden berberina.
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
GEP20207176B (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements